Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER

অনুযায়ী Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.
প্রকাশিত Ann Oncol (2015)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

অনুযায়ী Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J., Chia, S. K. L., Bernard, P. S., Nielsen, T. O., Ellis, M. J., Carey, L. A., Perou, C. M.
প্রকাশিত 2012

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial

অনুযায়ী Sipos, O., Tovey, H., Quist, J., Haider, S., Nowinski, S., Gazinska, P., Kernaghan, S., Toms, C., Maguire, S., Orr, N., Linn, S.C., Owen, J., Gillett, C., Pinder, S.E., Bliss, J.M., Tutt, A., Cheang, M.C.U., Grigoriadis, A.
প্রকাশিত Ann Oncol (2021)

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

অনুযায়ী Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., Lønning, P. E., Morden, J., Porta, N., Jassem, J., van De Velde, C. J., Rasmussen, B. B., Verhoeven, D., Bartlett, J. M. S., Coombes, R. C.
প্রকাশিত Breast Cancer Res Treat (2017)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

অনুযায়ী Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E
প্রকাশিত 2014